TX-PHILLIPS-66
19.7.2022 15:02:13 CEST | Business Wire | Pressemeddelelse
Phillips 66 (NYSE: PSX) og H2 Energy Europe ("H2 Energy") meddelte i dag, at de har indgået en 50-50 joint venture-aftale med henblik på etablering og drift af et netværk af brinttankstationer og skabelsen af et grønt brintøkosystem i Tyskland, Østrig og Danmark.
JET H2 Energy Austria GmbH (JET H2 Energy), som udgør joint venture-aftalen mellem datterselskaberne Phillips 66 Limited og H2 Energy Europe SA, forener Phillips 66's store ekspertise inden for detailhandel med H2 Energys erfaringer og ekspertise inden for brint. JET H2 Energy bliver en central aktør i branchen og vil sætte skub i udviklingen af brint som brændstof i Europa. Det nye selskab planlægger at etablere cirka 250 brinttankstationer inden 2026.
"Det er vores mål at gøre brint til en førende energibærer inden for emissionsfri mobilitet. Vi vil skabe ligevægt i de involverede aktørers interesser i hele brintværdikæden og skabe et bæredygtigt brintøkosystem,” udtaler Olaf Borbor, administrerende direktør for JET H2 Energy.
"Phillips 66 er med stor succes til stede på detailmarkedet i Europa med sit brand JET® . H2 Energy har en dokumenteret track record inden for skabelsen af et vellykket grønt brintøkosystem i Schweiz. Parternes kompetencer supplerer derfor hinanden ideelt i den næste fase i udviklingen af brintøkonomien."
JET H2 Energy vil søge og udvælge steder (greenfield-udvikling, JET® og kundesteder), etablere og drive brinttankstationer til både tunge og lette køretøjer og personbiler (FCEV'er), forsyne brinttankstationerne med grøn brint og opbygge relationer med kunder og originaludstyrsproducenter.
JET H2 Energy vil drage fordel af sit tætte samarbejde med Hyundai Hydrogen Mobility, der er eksklusiv europæisk forhandler af Hyundai Xcient-brintbrændselscellelastbilen.
Ledelsesteamet består af Olaf Borbor (CEO), Markus Wolf (CFO) og Jonas Erdmann (Commercial Manager). Det tyske hovedkvarter er baseret i Hamborg.
Phillips 66 Limited er en kombineret energiproduktions- og logistikvirksomhed hjemhørende i Storbritannien. Virksomheden er et datterselskab under og 100 % ejet af Phillips 66. Phillips 66 har med flere end 1.000 JET® -stationer en stærk tilstedeværelse på markedet i Europa og via joint venture-samarbejdet Coop Mineraloel AG et voksende netværk til optankning af brint i Schweiz.
H2 Energy Europe med hovedsæde i Schweiz er et joint venture mellem selskabet Trafigura Pte Ltd., der handler med råvarer, og H2 Energy Holding AG, en førende brintleverandør i Europa med investeringer i produktion, distribution og anvendelse af grøn brint. H2 Energy var gennem sine tilknyttede selskaber den første til at udvikle og levere brintbrændselscellelastbiler til kommercielle brugere og skabe et grønt brintbrændstof-økosystem i Schweiz.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220718005806/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum